https://www.selleckchem.com/pr....oducts/trastuzumab-d
Vildagliptin treatment led to improved relaxation and a reduction in senescence and SASP markers. Furthermore, in VSMCs DOX increased SA-β-gal activity, p16 , p27 , IL-6 and IL-8, and GLP1 treatment led to a decrease of both senescence and SASP markers. In summary we conclude that vildagliptin can reduce senescence and improve relaxation of vascular smooth muscle in the aorta of DOX-treated rats, and GLP-1 can reduce senescence of DOX-treated VSMCs. These data suggest that incretin-based drugs are promising candidates for